Table 5 Therapeutic interventions and outcomes of all patients with MAS. (n = 55)
Therapeutic intervention | SJIA (n = 34) | KD (n = 10) | SLE(n = 11) | Total (n = 55) |
|---|---|---|---|---|
Any corticosteroids | 34(100) | 10(100) | 11(100) | 55(100) |
Pulse methylprednisolone | 29(85.3) | 6(60) | 10(90.9) | 49(89.0) |
Cyclosporine | 25(73.5) | 2(20)* | 7(63.3) | 34(61.8) |
Intravenous immunoglobulin | 4(11.7) | 10(100)* | 3(27.2)‡ | 17(30.9) |
Biologic medications | 4(11.7) | 0(0) | 1(9.0) | 5(9.0) |
 Tocilizumab | 4(11.7) | 0(0) | 0(0) | 4(7.20) |
 Rituximab | 0(0) | 0(0) | 1(9.0) | 1(1.8) |
Cyclophosphamide | 0(0) | 0(0) | 1(9.0) | 1(1.8) |
Plasmapheresis | 0(0) | 0(0) | 1(9.0) | 1(1.8) |